US 12,404,267 B2
Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4H-chromene-2-carboxamide and of its mesylate salt
Petar Bibulić, Zagreb (HR); Dijana Škalec Šamec, Jastrebarsko (HR); Marina Marinkovic, Sesvete-Zagreb (HR); and Jasna Dogan, Petrinja (HR)
Assigned to ASSIA CHEMICAL INDUSTRIES LTD., Tel Aviv (IL)
Appl. No. 17/429,968
Filed by ASSIA CHEMICAL INDUSTRIES LTD., Tel Aviv (IL)
PCT Filed Feb. 14, 2020, PCT No. PCT/US2020/018204
§ 371(c)(1), (2) Date Aug. 11, 2021,
PCT Pub. No. WO2020/168144, PCT Pub. Date Aug. 20, 2020.
Claims priority of provisional application 62/930,044, filed on Nov. 4, 2019.
Claims priority of provisional application 62/885,846, filed on Aug. 13, 2019.
Claims priority of provisional application 62/820,900, filed on Mar. 20, 2019.
Claims priority of provisional application 62/805,425, filed on Feb. 14, 2019.
Prior Publication US 2022/0135548 A1, May 5, 2022
Int. Cl. C07D 405/14 (2006.01); A61K 31/4725 (2006.01); A61K 45/06 (2006.01)
CPC C07D 405/14 (2013.01) [A61K 31/4725 (2013.01); A61K 45/06 (2013.01); C07B 2200/13 (2013.01)] 14 Claims
 
1. Crystalline Form B of Encequidar (HM-30181A) mesylate, characterized by a PXRD pattern comprising peaks at 6.4, 7.6, 9.5, 14.6, 17.9, 18.7, 22.8, and 25.0 degrees 2-theta±0.2 degrees 2-theta.